EMA director Emer Cooke (Tomas Tkacik/Sipa USA via AP Images)

CHMP of­fers pos­i­tive opin­ion for two high-pro­file drugs as part of lat­est batch of rec­om­men­da­tions

When it comes to the Eu­ro­pean Med­i­cines Agency’s drug re­view com­mit­tee, known as CHMP, any pos­i­tive opin­ions it gives to a drug are all but cer­tain to be ap­proved across the EU. And the com­mit­tee just doled out opin­ions to a batch of 10 drugs, in­clud­ing two with high­er pro­files.

The Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use, aka CHMP, rec­om­mend­ed sev­en brand-name drugs and three gener­ic — for mar­ket­ing au­tho­riza­tion in the EU. And while the Eu­ro­pean Com­mis­sion has to sign off be­fore those drugs go to mar­ket, it’s rare that the com­mis­sion bucks the com­mit­tee’s choic­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.